Search | Page 5 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Prognostic models in predicting outcomes in myelodysplastic syndromes after hypomethylating agent failure

    ... March 28, 2017 Myelodysplastic syndromes (MDS) are clonal stem cell disorders marked by bone marrow ...

    Research Article last updated 04/14/2017 - 8:47am.

  2. Infectious complications in patients with myelodysplastic syndromes: a review of the literature with emphasis on patients treated with 5-azacitidine

    ... March 21, 2017 Myelodysplastic syndromes (MDS) are oligo-clonal diseases of the hematopoietic stem cell ...

    Research Article last updated 04/14/2017 - 10:41am.

  3. Cellular immune profiling after sequential clofarabine and lenalidomide for high risk myelodysplastic syndromes and acute myeloid leukemia

    ... Patients with high risk myelodysplastic syndromes (MDS) and acute myelogenous leukemia (AML) are commonly ...

    Research Article last updated 05/22/2017 - 11:42am.

  4. Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents

    ... Most anemic patients with non-deleted 5q lower-risk myelodysplastic syndromes (MDS) are treated with erythropoiesis-stimulating agents (ESAs), ...

    Research Article last updated 04/14/2017 - 9:09am.

  5. Relation between chelation and clinical outcomes in lower-risk patients with myelodysplastic syndromes: Registry analysis at 5 years

    ... of iron chelation therapy in patients with myelodysplastic syndromes . The present 5-year prospective registry analysis was conducted ...

    Research Article last updated 03/22/2017 - 11:24am.

  6. A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes

    ... to treat anemia in patients with lower-risk myelodysplastic syndromes (MDS) was evaluated in a phase 3 trial. Eligible patients had ...

    Research Article last updated 07/11/2017 - 10:16am.

  7. Self-reported sleep disturbance and survival in myelodysplastic syndromes

    ... survival (OS) are well understood for patients with myelodysplastic syndromes (MDS). New patients at our institution (n = 251; 2006-2014) ...

    Research Article last updated 03/22/2017 - 10:04am.

  8. Diagnostic Utility of Flow Cytometry in Myelodysplastic Syndromes.

    ... The pathological hallmark of myelodysplastic syndromes (MDS) is marrow dysplasia, which represents the basis of the WHO ...

    Research Article last updated 03/22/2017 - 9:18am.

  9. Management of lower-risk myelodysplastic syndromes without del5q: Current approach and future trends

    ... INTRODUCTION: Myelodysplastic syndromes (MDS) are characterized by progressive bone marrow failure ...

    Research Article last updated 03/22/2017 - 9:46am.

  10. Myelodysplastic Syndromes and Iron Chelation Therapy

    ... extrapolation of learnings from thalassemia to the myelodysplastic syndromes (MDS) has resulted in a fragmented and uncoordinated clinical ...

    Research Article last updated 03/22/2017 - 9:11am.